Wang GF, Shu CX, Cai XD, Wang HB, Xu JH, Jia YQ. Clinical efficacy of Gamma Knife® combined with transarterial chemoembolization and immunotherapy in the treatment of primary liver cancer. World J Gastrointest Surg 2024; 16(6): 1601-1608 [DOI: 10.4240/wjgs.v16.i6.1601]
Corresponding Author of This Article
Yu-Qing Jia, MD, Doctor, Department of General Surgery, Yangzhou Friendship Hospital Affiliated to Medical College of Yangzhou University, No. 446 Siwangting Road, Hanjiang District, Yangzhou 225000, Jiangsu Province, China. 13605251826@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jun 27, 2024; 16(6): 1601-1608 Published online Jun 27, 2024. doi: 10.4240/wjgs.v16.i6.1601
Table 1 Baseline characteristics of 51 patients with primary liver cancer, n (%)
Item
Case
Gender
Male
42 (82.35)
Female
9 (17.65)
Age
< 60
7 (13.73)
≥ 60
44 (86.27)
Viral infection
No
11 (21.57)
HBV
34 (66.67)
HCV
4 (7.84)
HBV + HCV
2 (3.92)
Child-Pugh grade
A
45 (88.24)
B
6 (11.76)
BCLC
B
11 (21.57)
C
40 (78.43)
Tumor number
1
20 (39.22)
≥ 2
31 (60.78)
Tumor diameter
< 5 cm
19 (37.25)
≥ 5 cm
32 (62.75)
Table 2 Clinical efficacy evaluation of 51 patients with primary liver cancer, n (%)
Item
Case
CR
0 (0)
PR
27 (52.94)
SD
16 (31.37)
PD
8 (15.69)
Objective response rate
27 (52.94)
Disease control rate
43 (84.31)
Table 3 Changes in liver function indices before and after treatment (mean ± SD)
Before (n = 51)
After (n = 51)
t
P value
ALT (U/L)
75.11 ± 4.62
60.62 ± 4.09
16.771
0
AST (U/L)
119.47 ± 11.69
41.57 ± 6.88
41.013
0
LDH (U/L)
439.15 ± 20.62
236.73 ± 18.15
52.623
0
AFP-13 (%)
18.52 ± 5.37
11.31 ± 2.65
8.598
0
Table 4 Incidence of adverse events, n (%)
Incidence
Grade 3-5
Hypertension
10 (19.61)
4 (7.84)
Platelet reduction
14 (27.45)
2 (3.92)
ALT elevation
7 (13.73)
1 (1.96)
Leukocyte reduction
13 (25.49)
3 (5.88)
Nausea and vomiting
20 (39.22)
1 (1.96)
Fever
3 (5.88)
0 (0.00)
Hypothyroidism
2 (3.92)
0 (0.00)
Abdominal pain
4 (7.84)
0 (0.00)
Hyperbilirubinemia
6 (11.76)
0 (0.00)
Ascites
3 (5.88)
0 (0.00)
Hypokalemia
2 (3.92)
0 (0.00)
Citation: Wang GF, Shu CX, Cai XD, Wang HB, Xu JH, Jia YQ. Clinical efficacy of Gamma Knife® combined with transarterial chemoembolization and immunotherapy in the treatment of primary liver cancer. World J Gastrointest Surg 2024; 16(6): 1601-1608